The NIBR Global Scholars Program (NGSP) is a competitive program designed for innovators from invited institutions to gain funding for breakthrough science not covered by traditional grant support. Through this program, NIBR supports projects focused on novel science with the objective of being translated to drug discovery and/or clinical research.

Curve of life world image

Resources for breakthrough science

Each Scholar will receive up to 1 mil USD funding over three years along with drug-hunting expertise from dedicated NIBR scientific collaborators. In addition, a dedicated alliance manager will ensure a productive collaboration environment between NIBR and the academic institution by handling all operational facets of the NGSP.

Access to inter-disciplinary expertise

Academic scholars have access to disease biology, drug-hunting and translational research expertise. Each selected scholar will join forces with other entrepreneurially motivated NIBR scientists to challenge the status quo and take bold risks for potential big rewards and will have an opportunity to advance research into early development stages.

Meet the 2022 recipients of the NIBR Global Scholars Program

With these distinguished scholars, we will focus on innovative medicines to address the worldwide burden of disease.

Meet the 2021 recipients

NGSP 2020 Scholars

Over 50 world-class institutions are participating in NGSP 2023

The following institutions have been invited to participate in the 2023 NGSP. We look forward to receiving their investigators’ proposals for innovative projects that will advance our mission to improve and extend peoples’ lives.

Academic Institution Academic Institution
Medical University Vienna AT Seoul National University Hospital KR
University of Vienna AT  Instituto de Medicina Molecular PT 
Monash University AU Boston University US 
University of Melbourne AU Brigham and Women’s Hospital US
UniQuest AU Columbia University US
WEHI (Walter & Eliza Hall Inst.) AU Weill Cornell Medicine US
Sunnybrook Research Institute CA Duke University US
The Hospital for Sick Children CA Emory University US
University of Toronto CA Fred Hutchinson Cancer Research Center US
ETH Zurich CH  Mass Eye and Ear US
University of Basel CH Massachusetts General Hospital US
University of Geneva CH Morehouse School of Medicine US
Geneva University Hospitals CH Northwestern University US
University of Zurich CH Ohio State University US
LMU Munich DE Rutgers, The State University of New Jersey US
University Hospital Munich DE Schepens Eye Research Institute
of Mass Eye and Ear		 US
Institut Pasteur FR Temple University US
Francis Crick Institute GB Tufts University US
Imperial College London GB University of California, Los Angeles US
University of Birmingham GB University of California, Berkeley US
University of Oxford GB University of California, San Diego US
Council of Scientific & Industrial Research -
Centre for Cellular and Molecular Biology (CSIR-CCMB)		 IN University of North Carolina at Chapel Hill US
Tel Aviv University IS University of Arizona US
Weizmann Institute of Science IS University of Chicago US
Kyoto University JP University of Massachusetts Chan Medical School US
Okinawa Institute of Science and Technology JP University of Michigan US
Osaka University JP University of Pittsburgh US
University of Tokyo JP Vanderbilt University US
Asan Medical Center KR Washington University in St. Louis US
    Yale University US